Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$618.90M+1071.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian J. Blaser
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 6,500
- Beta
- 0.68
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.25
Financials
Revenue
$618.90M+1072.0%Net Income
$-53.80MEBITDA
$112.10M+908.6%Free Cash Flow
$-1.40M-111.1%EPS (diluted)
$-0.78Shares Outstanding (diluted)
68.70M+108.8%Operating Expenses
$225.20MCash & Debt
$192.10MReturn of Capital
$0.00Revenue by Segment (annual)
$483.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.73B | $-1.13B | $-16.69 |
| 2024 | $2.78B | $-2.05B | $-30.54 |
| 2023 | $3.00B | $-10.10M | $-0.15 |
| 2022 | $3.27B | $548.70M | $9.66 |
| 2021 | $1.70B | $704.20M | $16.74 |
| 2020 | $1.66B | $810.29M | $19.24 |
| 2019 | $534.89M | $72.92M | $1.78 |
| 2018 | $522.28M | $74.18M | $1.74 |
| 2017 | $277.74M | $-8.16M | $-0.24 |
| 2016 | $191.60M | $-13.81M | $-0.42 |
| 2015 | $196.13M | $-6.08M | $-0.18 |
| 2014 | $182.62M | $-7.07M | $-0.21 |
| 2013 | $175.41M | $7.39M | $0.22 |
| 2012 | $155.74M | $4.99M | $0.15 |
Valuation
QDELhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·18d ago·Positive
QuidelOrtho Corporation (QDEL) Q3 2026 Earnings Call Transcript QuidelOrtho Corporation ( QDEL ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Sanjeev Sharma Brian Blaser - President, CEO & Director Micah Young - Chief Financial Officer & Principal Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Casey Woodring - JPMorgan…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call QuidelOrtho NASDAQ: QDEL reported third-quarter revenue of $619 million, down 12% year over year on a constant-currency basis, as China pricing changes and softer respiratory testing demand continued to weigh on results. The company said revenue rose 3% excluding China, respiratory testing and the prior-year contribution from its U.S. Donor Screening business, which it is winding down.
View source ↗ - Newszacks.com·19d ago·Positive
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates QuidelOrtho (QDEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.8 per share a year ago.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
…nnual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ― SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026. Key Third Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $619 million, a decrease of 12% both as reported and in constant…
View source ↗ - Newsprnewswire.com·24d ago·Positive
Transforming Data Into Actionable Insights in the Lab SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother. Laboratories are facing increasing complexity and growing testing demand.
View source ↗ - Newsprnewswire.com·38d ago·Negative
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan an…
View source ↗ - Newszacks.com·39d ago·Neutral
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.
View source ↗ - Newsprnewswire.com·46d ago·Neutral
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings more than 20 years of experience across investor relations, corporate strategy and equity research at global organizations.
View source ↗ - Newsprnewswire.com·59d ago·Neutral
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
View source ↗ - Newsprnewswire.com·87d ago·Neutral
Faster Answers, Better Decisions: ADLM 2026 Highlights SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: deliveri…
View source ↗ - Newszacks.com·97d ago·Neutral
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
View source ↗ - Newszacks.com·97d ago·Neutral
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth? QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
View source ↗ - Newszacks.com·97d ago·Positive
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher? QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
View source ↗ - Newszacks.com·104d ago·Neutral
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $0.25 per share
Typical surprise +40.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.31 vs $0.20beat
- Thu, Aug 6$0.13 vs $-0.05beat
- Tue, May 5$-0.04 vs $0.37miss
- Wed, Feb 11$0.46 vs $0.43beat
- Wed, Nov 5$0.80 vs $0.51beat
- Tue, Aug 5$0.12 vs $0.00beat
Estimates and results for QDEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QDEL officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Jun 23, 2021 (43d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Jun 12, 2021 (46d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Apr 10, 2021 (27d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Apr 10, 2021 (38d later)Sell$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 6, 2021 (11d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2020 (32d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (28d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 19, 2020 (20d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 19, 2020 (37d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 10, 2020 (33d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (26d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 16, 2020 (37d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 11, 2020 (40d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
